Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold (GABI-R)
2022年3月31日 更新者:IHF GmbH - Institut für Herzinfarktforschung
German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
The German-Austrian ABSORB Register shall provide an analysis of acute and long-term safety as well as therapy outcomes of the ABSORB (trade mark) bioresorbable vascular scaffold system in patients suffering from coronary artery disease.
研究概览
详细说明
The register collects prospective data regarding the quality of care of this therapy concept including specifically the following objectives:
- Documentation of all consecutive patients having been treated with the ABSORB biore-sorbable vascular scaffold system under clinical real-world conditions
- Documentation of indications, procedural results, and short and long-term outcomes
- Documentation of the technical performance of ABSORB implant procedures
- Collection of safety data, in particular documentation of hospital mortality, major non-fatal complications (especially myocardial infarction, Re-PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting), stroke, thrombosis)
- Documentation of long-term patient safety marked by mortality and major non-fatal complications (especially myocardial infarction, Re-PCI or CABG, stroke, thrombosis) at 30 days, 6 months, 2 years and 5 years
- Gathering of health economics data (capture of direct costs, especially with view to change of medication and outpatient/inpatient hospital services, and indirect costs) pre and post ABSORB implant
- Gathering data on the quality of life pre and post ABSORB implant to document individual QoL dimensions as well as QALY (quality adjusted life year) data
研究类型
观察性的
注册 (实际的)
3330
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Graz、奥地利
- Landeskrankenhaus-Univ.Klinikum Graz
-
Graz、奥地利
- LKH Graz-West
-
Innsbruck、奥地利
- Medizinische Universität Innsbruck
-
Linz、奥地利
- A.ö. Krankenhaus der Stadt Linz
-
Villach、奥地利
- LKH Villach
-
-
Wien
-
Vienna、Wien、奥地利、A-1090
- Medizinische Universität Wien
-
-
-
-
-
Arnstadt、德国
- Ilm-Kreis-Kliniken, Arnstadt-Ilmenau
-
Bad Berka、德国
- Zentralklinik Bad Berka
-
Bad Friedrichshall、德国
- SLK-Kliniken, Klinikum am Plattenwald
-
Bad Krozingen、德国
- Herzzentrum Bad Krozingen
-
Bad Langensalza、德国
- Hufeland Klinikum
-
Bad Nauheim、德国
- Kerckhoff-Klinik
-
Bad Oeynhausen、德国
- Herz- und Diabeteszentrum Nordrhein-Westfalen
-
Bad Segeberg、德国、23795
- Segeberger Kliniken Gmbh
-
Bad Segeberg、德国
- Segeberger Kliniken
-
Berlin、德国
- Vivantes Klinikum Neukölln
-
Berlin、德国
- Vivantes Klinikum Spandau
-
Berlin、德国
- Vivantes-Klinikum Am Urban
-
Berlin、德国
- Caritas-Klinik Pankow
-
Berlin、德国
- Charité - Universitätsmedizin Berlin - Campus Virchow-Klinikum
-
Berlin、德国
- Charité - Universitätsmedizin Berlin-Campus Benjamin Franklin
-
Berlin、德国
- Vivantesklinik im Friedrichshain
-
Bernau、德国
- Immanuel Klinikum Bernau
-
Bitterfeld-Wolfen、德国
- Gesundheitszentrum Bitterfeld-Wolfen
-
Bochum、德国
- St. Josef- und Elisabeth- Hospital
-
Bremen、德国
- Klinikum Links der Weser
-
Buchholz、德国
- Krankenhaus Buchholz
-
Coburg、德国
- Klinikum Coburg
-
Cottbus、德国
- Sana-Herzzentrum Cottbus
-
Darmstadt、德国
- Kardiovaskuläres Zentrum Darmstadt
-
Dresden、德国
- Praxisklinik Herz und Gefässe Dresden
-
Eberswalde、德国
- Werner-Forßmann-Krankenhaus
-
Eichstätt、德国
- Kliniken Im Naturpark Altmühltal, Klinik Eichstätt
-
Erlangen、德国
- Universitätsklinikum Erlangen
-
Essen、德国
- Universitätsklinikum Essen
-
Essen、德国
- Elisabeth Krankenhaus Essen
-
Essen、德国
- Alfried Krupp v. Bohlen Krankenhaus
-
Freiburg、德国
- Universitätsklinikum Freiburg
-
Fulda、德国
- Klinikum Fulda
-
Gelnhausen、德国
- Main-Kinzig-Kliniken
-
Gießen、德国、35392
- Universitätsklinikum Gießen
-
Greifswald、德国
- Universitätsklinikum Greifswald
-
Göttingen、德国
- Universitätsklinikum Göttingen
-
Hamburg、德国
- Asklepios Klinik St. Georg
-
Hamburg、德国
- Asklepios Klinik Harburg
-
Hamburg、德国
- Universitäres Herzzentrum Eppendorf
-
Hannover、德国
- Med. Hochschule Hannover
-
Heilbronn、德国
- SLK-Kliniken Heilbronn
-
Hennigsdorf、德国
- Oberhavel Kliniken-Klinik Hennigsdorf
-
Herford、德国
- Krankenhaus Herford
-
Immenstadt、德国
- Herz- und Gefäßzentrum Oberallgäu-Kempten
-
Itzehoe、德国
- Klinikum Itzehoe
-
Kempten、德国、87439
- Herz- und Gefäßzentrum Oberallgäu/Kempten
-
Koblenz、德国
- Stiftungsklinikum Mittelrhein
-
Köln、德国
- Herzzentrum Universitätsklinikum Köln
-
Leipzig、德国
- Universitätsklinikum Leipzig
-
Ludwigshafen am Rhein、德国、67063
- Klinikum Ludwigshafen
-
Lübeck、德国
- Universitatsklinikum Schleswig Holstein
-
Lüdenscheid、德国
- Klinikum Lüdenscheid
-
Lünen、德国
- St. Marien-Hospital
-
Magdeburg、德国
- Universitätsklinikum Magdeburg
-
Mainz、德国
- Universitätsklinikum Mainz
-
Mannheim、德国
- Universitätsklinikum Mannheim
-
Marburg、德国
- Universitätsklinikum Marburg
-
Munich、德国
- Deutsches Herzzentrum München
-
Munich、德国
- Klinikum München-Bogenhausen
-
Munich、德国
- Isar Herz Zentrum München
-
Munich、德国
- Klinikum der Universität München , Campus Großhadern
-
Munich、德国
- Städtisches Klinikum München - Neuperlach
-
Mönchengladbach、德国
- Krankenhaus St. Franziskus Mönchengladbach
-
Mülheim、德国
- Evangelisches Krankenhaus Mülheim
-
Rostock、德国
- Universitatsmedizin Rostock
-
Rüsselsheim、德国
- GPR Klinikum Rüsselsheim
-
Siegen、德国
- St. Marien-Krankenhaus
-
Stade、德国
- Elbe Klinikum Stade
-
Suhl、德国
- SRH Zentralklinikum Suhl
-
Ulm、德国
- Universitatsklinikum Ulm
-
Vechta、德国
- St. Marienhospital
-
Villingen-Schwenningen、德国
- Schwarzwald-Baar Klinikum
-
Winnenden、德国
- Rems-Murr-Klinik Winnenden
-
Zwickau、德国
- Heinrich-Braun-Krankenhaus
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
All patients in Germany and Austria having been implanted with ABSORB scaffold system
描述
Inclusion Criteria:
- ABSORB implant scheduled
- Age 18+
- Patients giving consent to keep scheduled follow-ups
- Signed informed consent
Exclusion Criteria:
- None
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Implantation of ABSORB Scaffold
Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
|
Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of serious adverse cardiac events
大体时间:5 years after index procedure
|
The following events will be evaluated:
|
5 years after index procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Success of ABSORB implantation
大体时间:during implantation of ABSORB scaffold
|
The following parameters will be evaluated to assess procedural outcome:
|
during implantation of ABSORB scaffold
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Effectiveness of ABSORB implantation
大体时间:5 years follow-up period
|
Effectiveness of ABSORB implantation will be assessed based on the following parameters:
|
5 years follow-up period
|
Change in quality of life
大体时间:5 years follow-up period
|
Changes in quality of life will be assessed by measuring
|
5 years follow-up period
|
Health-economical effects of ABSORB scaffold implantation
大体时间:5 years follow-up period
|
Health-economical effects will be assessed by measuring
|
5 years follow-up period
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Christian Hamm, Prof. Dr.、University Clinic Giessen and Kerckhoff-Clinic Bad Nauheim
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Nef H, Wiebe J, Achenbach S, Munzel T, Naber C, Richardt G, Mehilli J, Wohrle J, Neumann T, Biermann J, Zahn R, Kastner J, Schmermund A, Pfannebecker T, Schneider S, Limbourg T, Hamm CW. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R). Cardiovasc Revasc Med. 2016 Jan-Feb;17(1):34-7. doi: 10.1016/j.carrev.2015.09.002. Epub 2015 Sep 10.
- Mehilli J, Achenbach S, Woehrle J, Baquet M, Riemer T, Muenzel T, Nef H, Naber C, Richardt G, Zahn R, Gori T, Neumann T, Kastner J, Schmermund A, Hamm C. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R. EuroIntervention. 2017 Dec 20;13(11):1319-1326. doi: 10.4244/EIJ-D-17-00291.
- Nef HM, Wiebe J, Kastner J, Mehilli J, Muenzel T, Naber C, Neumann T, Richardt G, Schmermund A, Woehrle J, Zahn R, Riemer T, Achenbach S, Hamm CW. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention. 2017 Dec 20;13(11):1311-1318. doi: 10.4244/EIJ-D-17-00330.
- Wohrle J, Nef HM, Naber C, Achenbach S, Riemer T, Mehilli J, Munzel T, Schneider S, Markovic S, Seeger J, Rottbauer W, Pfannebecker T, Richardt G, Zahn R, Gori T, Kastner J, Schmermund A, Hamm CW; GABI-R Study Group. Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy. Coron Artery Dis. 2018 Aug;29(5):389-396. doi: 10.1097/MCA.0000000000000618.
- Huseynov A, Baumann S, Nef H, Riemer T, Schneider S, Pfannenbecker T, Achenbach S, Mehilli J, Munzel T, Gori T, Wohrle J, Zahn R, Kastner J, Schmermund A, Richardt G, Hamm CW, Akin I. Comparison between treatment of "established" versus complex "off-label" coronary lesions with Absorb(R) bioresorbable scaffold implantation: results from the GABI-R(R) registry. Clin Res Cardiol. 2020 Mar;109(3):374-384. doi: 10.1007/s00392-019-01517-8. Epub 2019 Jun 29.
- Hemetsberger R, Abdelghani M, Mankerious N, Allali A, Toelg R, Gori T, Achenbach S, Riemer T, Mehilli J, Nef HM, Naber C, Wohrle J, Zahn R, Kastner J, Schmermund A, Hamm C, Munzel T, Richardt G; GABI-R Study Group. Impact of coronary calcification on outcomes after ABSORB scaffold implantation: insights from the GABI-R registry. Coron Artery Dis. 2020 Nov;31(7):578-585. doi: 10.1097/MCA.0000000000000870.
- Gori T, Achenbach S, Riemer T, Mehilli J, Nef HM, Naber C, Richardt G, Wohrle J, Zahn R, Neumann T, Kastner J, Schmermund A, Hamm C, Munzel T. Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R Registry. J Clin Med. 2019 May 30;8(6):767. doi: 10.3390/jcm8060767.
- Pahmeier K, Neusser S, Hamm C, Kastner J, Wohrle J, Zahn R, Achenbach S, Mehilli J, Gori T, Naber C, Nef H, Neumann T, Richardt G, Schmermund A, Claas C, Riemer T, Biermann-Stallwitz J; GABI-R Study Group. Quality of life of patients with coronary heart disease treated with the bioresorbable vascular scaffold (ABSORB): 2-year results from the GABI-R-registry. BMC Cardiovasc Disord. 2022 Aug 20;22(1):379. doi: 10.1186/s12872-022-02815-2.
- Wein B, Zaczkiewicz M, Graf M, Zimmermann O, Gori T, Nef HM, Kastner J, Mehilli J, Richardt G, Wohrle J, Achenbach S, Riemer T, Hamm C, Torzewski J. No Difference in 30-Day Outcome and Quality of Life in Transradial Versus Transfemoral Access - Results From the German Austrian ABSORB Registry (GABI-R). Cardiovasc Revasc Med. 2022 Jul;40:144-149. doi: 10.1016/j.carrev.2021.11.022. Epub 2021 Nov 24.
- Boeder NF, Kastner J, Mehilli J, Munzel T, Naber C, Neumann T, Richardt G, Schmermund A, Wohrle J, Zahn R, Riemer T, Achenbach S, Hamm CW, Nef HM; GABI-R Study Group. Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the German-Austrian ABSORB RegIstRy. Catheter Cardiovasc Interv. 2021 Oct;98(4):E555-E563. doi: 10.1002/ccd.29829. Epub 2021 Jun 18.
- Zaczkiewicz M, Wein B, Graf M, Zimmermann O, Kastner J, Wohrle J, Thomas R, Hamm C, Torzewski J; GABI-R Study Group. Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of </=18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R). Int J Cardiol Heart Vasc. 2020 Mar 20;27:100501. doi: 10.1016/j.ijcha.2020.100501. eCollection 2020 Apr.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年11月8日
初级完成 (实际的)
2016年1月31日
研究完成 (实际的)
2021年7月6日
研究注册日期
首次提交
2014年1月20日
首先提交符合 QC 标准的
2014年2月17日
首次发布 (估计)
2014年2月19日
研究记录更新
最后更新发布 (实际的)
2022年4月1日
上次提交的符合 QC 标准的更新
2022年3月31日
最后验证
2021年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
ABSORB Scaffold的临床试验
-
Abbott Medical Devices完全的冠状动脉疾病 | 冠心病 | 冠状动脉闭塞 | 冠状动脉慢性完全闭塞 | 冠状动脉再狭窄 | 冠状动脉狭窄 | 冠状动脉再狭窄比利时
-
The University of New South Wales终止
-
Belfast Health and Social Care TrustBristol Royal Infirmary; Royal Infirmary of Edinburgh; Golden Jubilee National Hospital未知
-
Ottawa Heart Institute Research Corporation撤销冠状动脉疾病 | 糖尿病
-
Azienda Ospedaliera Bolognini di Seriate Bergamo未知
-
Corporacion Parc TauliDepartment of Health, Generalitat de Catalunya; Fundació Parc Taulí完全的